Skin targeted lipid vesicles as novel nano-carrier of ketoconazole: characterization, in vitro and in vivo evaluation

Journal of Materials Science: Materials in Medicine

Volumn 26, Issue 4, 2015, Pages 1-13

  Guo, Fang ^a   Wang, Jinping ^a   Ma, Man ^a   Tan, Fengping ^a   Li, Nan ^a  

^a TIANJIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CONFOCAL MICROSCOPY; DEFORMATION; DRUG DELIVERY; DRUG PRODUCTS; DRUG THERAPY; FUNGI; LIPOSOMES; PARTICLE SIZE; POLYDISPERSITY; SODIUM DODECYL SULFATE; SODIUM SULFATE; TRANSMISSION ELECTRON MICROSCOPY;

ANTI-FUNGAL ACTIVITY; CONFOCAL LASER SCANNING MICROSCOPY; DEFORMABLE LIPOSOMES; ENTRAPMENT EFFICIENCY; POLYDISPERSITY INDICES; SPHERICAL STRUCTURES; TARGETING DELIVERIES; TOPICAL DRUG DELIVERIES;

ANTIFUNGAL AGENTS;

ALCOHOL; DODECYL SULFATE SODIUM; KETOCONAZOLE; LIPOSOME; ANTIFUNGAL AGENT; NANOCAPSULE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONFOCAL LASER MICROSCOPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; IN VITRO STUDY; IN VIVO STUDY; LIPID VESICLE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SKIN; SKIN CANDIDIASIS; SWINE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DIFFUSION; PATHOLOGY; PHYSIOLOGY; PIG; SKIN ABSORPTION; STAPHYLOCOCCAL SKIN INFECTIONS; TREATMENT OUTCOME;

CANDIDA ALBICANS; RATTUS; SUS;

ANIMALS; ANTIFUNGAL AGENTS; DIFFUSION; IN VITRO TECHNIQUES; KETOCONAZOLE; LIPOSOMES; NANOCAPSULES; RATS; SKIN; SKIN ABSORPTION; STAPHYLOCOCCAL SKIN INFECTIONS; SWINE; TREATMENT OUTCOME;

EID: 84926476108     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-015-5487-2     Document Type: Article

References (46)

1. Odds FC, Miline LJ, Gentles JC, Hazel Ball E. The activity in vitro and in vivo of a new imidazole antifungal, ketoconazole. J Antimicrob Chemother. 1980;6:97–104.
2. Custem JV. The antifungal activity of ketoconazole. Am J Med. 1983;74:9–15.
3. FDA Drug Safety Communications, 2013. FDA limits usage of Nizoral (ketoconazole) oral tablets due to potential fatal liver injury and risk of drug interactions and adrenal gland problems.
4. Bouwatra JA, Honeywell-Nguyen PL, Gooris GS, Ponec M. Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res. 2003;42:1–46.
5. Schreier H, Bouwatra J. Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Control Release. 1994;30:1–15.
6. Kirjavainen M, Arto U, Jaaskelainen I, Sobhonen TM, Paronen P, Valjakka-Koskela R, Kiesvaara J, Monkkonen J. Interaction of liposomes with human skin in vitro-The influence of lipid composition and structure. Biochim Biophys Acta. 1996;1304:179–89.
7. Sinico C, Manconi M, Peppi M, Lai F, Valenti D, Fadda AM. Liposomes as carriers for dermal delivery of tretinon: in vitro evaluation of drug permeation and vesicle-skin interaction. J Control Release. 2005;103:123–36.
8. Jain S, Tiwary AK, Sapra B, Jain NK. Formulation and evaluation of ethosomes for transdermal delivery of lamivudine. AAPS Pharm Sci Tech. 2007;21:E1–9.
9. Gillet A, Lecomte F, Hubert P, Ducat E, Evrard B, Piel G. Skin penetration behavior of liposomes as a function of their composition. Eur J Pharm Biopharm. 2011;79:43–53.
10. Qiu Y, Gao Y, Hu K, Li F. Enhancement of skin permeation of docetaxel: a novel approach combining microneedle and elastic liposomes. J Control Release. 2008;129:144–50.
11. Song CK, Balakrishnan P, Shim CK, Chung SJ, Chong S, Kim DD. A novel vesicular carrier, transethosome, for enhanced skin delivery of voriconazole: characterization and in vitro/in vivo evaluation. Colloids Surf B. 2012;92:299–304.
12. Zheng WS, Fang XQ, Wang LL, Zhang YJ. Preparation and quality assessment of itraconazole transfersomes. Int J Pharm. 2012;436:291–8.
13. Touitou E, Dayan N, Bergelson L, Godin B. Ethosomes—novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release. 2000;65:403–18.
14. Dayan N, Touitou E. Carrrers for skin delivery of trihexyphenidyl HCl: ethosomes vs. liposmes. Biomaterials. 2000;21:1879–85.
15. Dubey V, Mishra D, Dutta T, Saraf M, Jain NK. Dermal and transdermal delivery of an antipsoriatic agent via ethanolic liposomes. J Control Release. 2007;123:148–54.
16. Verma P, Pharm B, Pharm M, Pathak K. Nanosized ethanolic vesicles loaded with econazole nitrate for the treatment of deep fungal infections through topical gel formulation. Nanomedicine. 2012;8:489–96.
17. Li G, Fan Y, Fan C, Li X, Wang X, Li M, Liu Y. Tacrolimus-loaded ethosomes: physicochemical characterization and in vivo evaluation. Eur J Pharm Biopharm. 2012;82:49–57.
18. Pradhan M, Singh D, Singh MR. Novel colloidal carrier for psoriasis: current issues, mechanistic insight and novel delivery approaches. J Control Release. 2013;170:380–95.
19. Lee EH, Oh A, Kim YK. Effect of edge activators on the formation and transfection efficiency of ultradeformable liposomes. Biomaterials. 2005;26:205–10.
20. Oh EK, Jin SE, Park JS, Park Y, Kim CK. Retained topical delivery of 5-aminolevulinic acid using cationic ultradeformable liposomes for photodynamic therapy. Eur J Pharm Sci. 2012;44:149–57.
21. Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gryadients and hydration force. Biochim Biophys Acta. 1992;1104:226–32.
22. Trotta M, Peira E, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int J Pharm. 2004;260:119–25.
23. Kombath RV, Minumula SK, Sockalingam A, Subadhra S, Parre S, Reddy RT, David B. Critical issues related to transfersomes-novel vesicular system. Acta Aci Pol Technol Aliment. 2012;11:67–82.
24. Honeywell-Nguyen PL, de Graaff AM, Groenink HW, Bouwstra JA. The in vivo and in vitro interactions of elastic and rigid vesicles with human skin. Biochim Biophys Acta. 2002;1573:130–40.
25. Honeywell-Nguyen PL, Gooris GS, Bouwstra JA. Quantitative assessment of the transport of elastic and rigid vesicle components and a model drug from these vesicle formulations into human skin in vivo. J Invest Dermatol. 2004;123:902–10.
26. Honeywell-Nguyen PL, Bouwstra JA. Vesicles as a tool for transdermal and dermal delivery. Drug Discov Today. 2005;2:67–74.
27. Liu D, Hu H, Lin Z, Chen D, Zhu Y, Hou S, Shi X. Quercetin deformable liposome: preparation and efficacy against ultraviolet B induced skin damages in vitro and in vivo. J Photochem Photobiol B. 2013;127:8–17.
28. Gupta PN, et al. Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. Int J Pharm. 2005;293:73–82.
29. Van den Bergh BAI, et al. Elasticity of vesicles assessed by electron spin resonance, electron microscopy and extrusion measurements. Int J Pharm. 2001;217:13–24.
30. Bronaugh RL, Stewart RF, Congdon ER. Methods for in vitro percutaneous absorption studies II. Animal models for human skin. Toxicol Appl Pharmacol. 1982;62:481–8.
31. Sullivan TP, Eaglstein WH, Davis SC, Mertz P. The pig as a model for human wound healing. Wound Repair Regen. 2001;9:66–76.
32. Eskandar NG, Simovie A, Prestidge CA. Nanoparticle coated submicron emulsions: sustained in vitro release and improved dermal delivery of all-trans-retinol. Pharm Res. 2009;26:1764–73.
33. Panchagnula R, Desu H, Jain A, Khandavilli S. Effect of lipid bilayer alteration on transdermal delivery of a high-molecular-weight and lipophilic drug: studies with paclitaxel. J Pharm Sci. 2004;93:2177–83.
34. Howes D, Guy R, Hadgraft J, Heylings J, Hoeck U, Kemper F, et al. Methods for assessing percutaneous absorption: the report and recommendations of ECVAM Workshop 13. Altern Lab Anim. 1996;24:81–106.
35. Uchida K, Tanaka T, Yamaguchi H. Achievement of complete mycological cure by topical antifungal agent NND-502 in guinea pig model of tinea pedis. Mircrobiol Immunol. 2003;47:143–6.
36. Tatsumi Y, Yokoo M, Arika T, Yamaguchi H. In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother. 2001;45:1493–9.
37. El Maghraby GM, Williams AC, Barry BW. Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. Int J Pharm. 2004;276:143–61.
38. El Maghraby GM, Williams AC, Barry BW. Skin delivery of oestradiol from deformable and traditional liposomes: mechanistic studies. J Pharm Pharmacol. 1999;51:1123–34.
39. El Maghraby GM, Barry BW, Williams AC. Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci. 2008;34:203–22.
40. El Maghraby GM, Williams AC, Barry BW. Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. Int J Pharm. 2004;275:143–61.
41. Prausnita MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26:1261–7.
42. El Maghraby GM, Williams AC, Barry BW. Can drug bearing liposomes penetrate intact skin? J Pharm Pharmacol. 2006;58:415–29.
43. Touitou E, Godin B, Dayan N, Weiss C, Piliponsky A, Levi-Schaffer F. Intracellular delivery mediated by an ethosomal carrier. Biomaterials. 2001;22:3053–9.
44. Li G, Fan C, Li X, Liu Y. Preparation and in vitro evaluation of tacrolimus-loaded ethosomes. Sci World J. 2012;2012:1–6.
45. Valenta C, Janisch M. Permeation of cyproterone acetate through pig skin from different vehicles with phospholipids. Int J Pharm. 2003;258:133–9.
46. Verma DD, Verma S, Blume G, Fahr A. Particle size of liposomes influences dermal delivery of substance into skin. Int J Pharm. 2003;258:141–51.